Posted by Michael Wonder on 20 Oct 2025
Ipsen’s Bylvay launches in Korea with national coverage for a rare childhood liver disease
20 October 2025 - Ipsen Korea has rolled out Bylvay (odevixibat) in Korea with national health insurance coverage, giving children with progressive familial intrahepatic cholestasis -- a rare genetic liver disease that until now left liver transplant as the only lifeline -- a long-awaited oral alternative.
Approved in the US and Europe in 2021, Bylvay became the first drug selected under Korea’s parallel approval, evaluation, and pricing pilot program in 2023. Reimbursement took effect this October, making Korea the first country in Asia to cover the therapy.
